Showing results (71-80 of 77) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate CancerCora Sternberg, Andrew Armstrong, Roberto Pili, et al.Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA TrialPhuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.Pageof 8